Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00642681
Other study ID # MKC-TI-112
Secondary ID
Status Completed
Phase Phase 2
First received March 21, 2008
Last updated December 1, 2014
Start date December 2007
Est. completion date August 2008

Study information

Verified date December 2014
Source Mannkind Corporation
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Observational

Clinical Trial Summary

Effect of upper respiratory infection (URI) on diabetic subjects with a meal challenge


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date August 2008
Est. primary completion date July 2008
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Subjects will have met the same inclusion criteria as MKC-TI-030

- Clinical diagnosis of URI with in 24 hrs prior to clinic visit and/or day of clinic visit

- At least 3 URI symptoms

Exclusion Criteria:

- Prior participation in MKC-TI-112

- MedHist, PE or lab findings of acute bacterial infection including but not limited to sputum prod., nasal/eye discharge, chest exam abnormalities, CXR findings of pneumonia.

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Intervention

Drug:
Technosphere Insulin
Technosphere® Insulin (TI) Inhalation Powder, prandial

Locations

Country Name City State
Canada Parkwood Hospital London Ontario
Russian Federation Kemerovo State Medical Academy of Ministry of Health Kemerovo RUS
Russian Federation NHI Kemerovo Regional Clinical Hospital Kemerovo RUS
Russian Federation FSI Principal Military Clinical Hospital n.a. academician N.N. Burdenko of the Ministry of Defense Moscow
Russian Federation RAAMS Endocrinology and Diabetology Department Moscow RUS
Russian Federation Russian State Medical University City Hospital # 4 Moscow RUS
Russian Federation Clinical Pharm Dept of Yaroslavl Clin Hospital Yaroslavl RUS
Russian Federation NHI Yaroslavl Regional Clinical Hospital Yaroslavl RUS
Russian Federation Yaroslavl Regional Clinical Hospital Yaroslavl RUS
United States New Mexico Clinical Research & Osteoporosis Center Albuquerque New Mexico
United States MODEL Clinical Research Baltimore Maryland
United States Billings Clinic Research Division Billings Montana
United States Cedar-Crosse Research Center Chicago Illinois
United States Rapid Medical Research Inc Cleveland Ohio
United States Private Practice Decatur Georgia
United States Healthcare Research Florissant Missouri
United States Valley Research (Norwood) Fresno California
United States Diabetes/Lipid Management and Research Center Huntington Beach California
United States Magna Center for Family Medicine Magna Utah
United States Your Diabetes Endocrine Nutrition Group Mentor Ohio
United States M.E.R.I. New York New York
United States Endocrine Research Solutions, Inc. Roswell Georgia
United States Diabetes & Glandular Disease Research Assoc PA San Antonio Texas
United States Arizona Research Associates Tuscon Arizona

Sponsors (1)

Lead Sponsor Collaborator
Mannkind Corporation

Countries where clinical trial is conducted

United States,  Canada,  Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary To measure Serum FDKP AUC 4 Hours No
See also
  Status Clinical Trial Phase
Completed NCT03743779 - Mastering Diabetes Pilot Study
Completed NCT03786978 - Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus N/A
Completed NCT01804803 - DIgital Assisted MONitoring for DiabeteS - I N/A
Completed NCT05039970 - A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04068272 - Safety of Bosentan in Type II Diabetic Patients Phase 1
Completed NCT03243383 - Readmission Prevention Pilot Trial in Diabetes Patients N/A
Completed NCT03730480 - User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS) N/A
Recruiting NCT02690467 - Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm. N/A
Completed NCT02229383 - Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus Phase 3
Completed NCT06181721 - Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT04489043 - Exercise, Prediabetes and Diabetes After Renal Transplantation. N/A
Withdrawn NCT03319784 - Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients Phase 4
Completed NCT03542084 - Endocrinology Auto-Triggered e-Consults N/A
Completed NCT02229396 - Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo Phase 3
Recruiting NCT05544266 - Rare and Atypical Diabetes Network
Completed NCT01892319 - An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
Completed NCT05031000 - Blood Glucose Monitoring Systems: Discounter Versus Brand N/A
Recruiting NCT04039763 - RT-CGM in Young Adults at Risk of DKA N/A